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Abstract
Bacillus anthracis produces a binary toxin composed of protective antigen (PA) and one of two subunits, lethal factor (LF) or
edema factor (EF). Most studies have concentrated on induction of toxin-specific antibodies as the correlate of protective
immunity, in contrast to which understanding of cellular immunity to these toxins and its impact on infection is limited. We
characterized CD4+ T cell immunity to LF in a panel of humanized HLA-DR and DQ transgenic mice and in naturally exposed
patients. As the variation in antigen presentation governed by HLA polymorphism has a major impact on protective
immunity to specific epitopes, we examined relative binding affinities of LF peptides to purified HLA class II molecules,
identifying those regions likely to be of broad applicability to human immune studies through their ability to bind multiple
alleles. Transgenics differing only in their expression of human HLA class II alleles showed a marked hierarchy of immunity to
LF. Immunogenicity in HLA transgenics was primarily restricted to epitopes from domains II and IV of LF and promiscuous,
dominant epitopes, common to all HLA types, were identified in domain II. The relevance of this model was further
demonstrated by the fact that a number of the immunodominant epitopes identified in mice were recognized by T cells
from humans previously infected with cutaneous anthrax and from vaccinated individuals. The ability of the identified
epitopes to confer protective immunity was demonstrated by lethal anthrax challenge of HLA transgenic mice immunized
with a peptide subunit vaccine comprising the immunodominant epitopes that we identified.
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Introduction
Whether viewed as a threat to human health in anthrax
endemic regions, as a bioweapon, or as a potentially devastating
pathogen of livestock, there is pressing need to gain better insights
into the immune response to Bacillus anthracis. The urgency has
been underlined by recent clusters of fatal and and near-fatal
anthrax infections among European intravenous drug users [1–4].
The pagA, lef and cya genes encode the three toxins associated
with pathogenicity: protective antigen (PA), lethal factor (LF) and
edema factor (EF). PA binds to the host cell surface receptors,
tumor endothelial marker 8 (TEM8) and capillary morphogenesis
gene 2 protein (CMG2) [5,6], with recent work suggesting that
a4b1- and a5b1-integrin complexes can also bind PA [7]. PA then
complexes with LF to form Lethal toxin (LT), which is
translocated into the host cell cytoplasm. LT is implicated in
several aspects of host immune subversion. It interferes with
antigen presenting cell (APC) function in the priming of adaptive
immunity: expression of the co-stimulatory molecules CD40,
CD80 and CD86 on dendritic cells, essential for the induction of
adaptive immunity in CD4+ T cells, are down-regulated in the
presence of LT [8]. Furthermore, LT can induce selective
apoptosis of activated macrophages by disrupting the TLR
dependant, p38 mediated, NF-kb regulation and expression of
pro-survival genes. LT also has a role in impairing B cell function,
reducing proliferation in response to TLR2, TLR4, BCR, and
CD40 [9]. Natural killer T (NKT) cells are shifted by LT from an
activated to anergic state [10,11].
Vaccination strategies in anthrax infection have been largely
dominated by PA [12,13]. For more than 40 years the major
vaccines used to protect against anthrax have been the AVA
(Biothrax) vaccine in the US, a filtered supernatant from the
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Sterne strain of B. anthracis, and AVP vaccine in the UK, an alum-
precipitated, cell-free culture supernatant of the Sterne strain
containing PA and a variable, minor, amount of LF. Both the
AVA and AVP vaccines require extensive vaccination regimens,
involving annual boosters. With concerns about the levels of
immunity induced by these vaccines and the high rates of adverse
effects [14,15], there have been efforts to design effective next-
generation vaccines with improved immunogenicity and low
reactogenicity [12]. Strategies to develop recombinant protein
vaccines have centered largely on PA [16]. PA based vaccines can
elicit humoral immunity while avoiding the adverse reactions
associated with older, filtrate based vaccines [17–19]. Recent
vaccination programmes have investigated the impact of HLA
polymorphisms, revealing considerable genetic variability in
responses of human donors, notably, the very low response of
HLA-DQB1*0602 individuals [20,21].
However, the rapid decrease in humoral immune responses
against PA observed in both humans and rabbits following the
cessation of boosting with either filtrate based or recombinant PA
(rPA) vaccines suggests that anti-PA humoral immunity induced by
these vaccines may not be long-lasting [22–24]. The development
of PA antibodies has also been shown to vary greatly within
infected human populations [25,26]. This in combination with
evidence that PA-based vaccines may provide protection against
lethal challenge with only select strains of B.anthracis [27], indicates
that the induction of anti-PA antibody responses should not be the
sole strategy for anthrax vaccination. Previous research has also
indicated that co-immunization with a range of B. anthracis
antigens, such as the capsular poly-c-D-glutamic acid, surface
polysaccharides, or toxins may augment the development of
protective immunity [28–30].
Analysis of naturally-infected humans in Zimbabwe showed that
most individuals mounted a response to both LF and PA [31]. We
recently studied the CD4+ T cell immune repertoire in patients
from the Kayseri region of Turkey who had become infected with
B. anthracis and had been hospitalised for cutaneous anthrax
following contact with infected livestock [32]. The study encom-
passed individuals who had suffered severe sepsis and undergone
protracted antibiotic therapy. Contrary to expectation from our
knowledge of immune subversion by LT in experimental settings,
we found robust immune memory to anthrax components, with
particular focus on domain IV of LF. Importantly, we were able to
quantify CD4+ T cell memory responses in naturally exposed
cutaneous anthrax patients and in AVP vaccinees, concluding that
the T cell response in the former group was equally strong in
response to both PA and LF, while in the latter group the major
response was to LF. This prompted us to reappraise CD4+ T cell
immunity to anthrax LF in detail.
For many microbial pathogens there is strong evidence for HLA
polymorphisms as determinants of disease risk, through variable
effects on the strength of immune response [33,34]. Different HLA
class II sequences vary in the anchor residues of the peptide
binding groove, presenting different peptides from a given antigen,
which will have an effect on the responding T cell repertoire [35].
While such studies are clearly pertinent to pathogens such as B.
anthracis which are variably lethal to infected humans, no such
analysis has been prevoiously undertaken.
In the present study, we characterize the CD4+ T cell immune
response to LF in HLA class II transgenic mice and in infected and
vaccinated humans. We observed that LF is highly immunogenic,
and that specific domains and epitopes show variable immuno-
dominance depending on HLA class II expression, with a
hierarchy of response to the toxin determined by HLA class II
polymorphism. This is the first time that such effects have been
described in the context of anthrax. Importantly, we define highly
immunodominant epitopes, common to all HLA types screened.
The CD4+ T cell epitopes were incorporated into a peptide
subunit vaccine and its protective immunity demonstrated in HLA
transgenic mice following live anthrax challenge.
Results
Anthrax lethal factor (LF) primes strong CD4 T cell
immunity with HLA-specific focus on different domains
Different HLA class II molecules vary in their peptide binding
specificity and so present different peptides of a given antigen,
with consequences for the CD4+ T cell repertoire activated
during the immune response. As a reductionist tool for
dissecting the role of individual HLA heterodimers we used
mice transgenic for each of the human HLA alleles, DRB1*0101
(HLA-DR1), DRB1*1501 (HLA-DR15), DRB1*0401 (HLA-
DR4), DQB1*0302 (HLA-DQ8) and DQB1*0602 (HLA-DQ6)
in the absence of endogenous MHC class II expression.
Following immunization with recombinant LF, all HLA
transgenic mice responded to LF protein, but responses to the
four domains of which the protein is composed varied (Figure 1).
Using mouse strains differing only in their expression of human
HLA class II alleles, we found a pronounced hierarchy of
response, with HLA-DR1 transgenics mounting a considerably
larger response than HLA-DQ6, DR15 or DR4 transgenics, and
HLA-DR4 transgenics showing the weakest response
(Figure 1A). This was not a simple reflection of strain differences
in HLA transgene expression or CD4+ positive selection, as the
least responsive strain, HLA-DR4, shows the highest level of
HLA class II expression (data not shown). Of particular interest
with respect to diversity of outcomes during infection of outbred
human populations, expression of different HLA class II alleles
was associated with a focus on different domains of the LF
molecule. LF immunized HLA-DR1 transgenics showed an
elevated response specifically to restimulation with LF domains
Author Summary
Anthrax is of concern with respect to human exposure in
endemic regions, concerns about bioterrorism and the
considerable global burden of livestock infections. The
immunology of this disease remains poorly understood.
Vaccination has been based on B. anthracis filtrates or
attenuated spore-based vaccines, with more recent trials
of next-generation recombinant vaccines. Approaches
generally require extensive vaccination regimens and
there have been concerns about immunogenicity and
adverse reactions. An ongoing need remains for rationally
designed, effective and safe anthrax vaccines. The impor-
tance of T cell stimulating vaccines is inceasingly recog-
nized. An essential step is an understanding of immuno-
dominant epitopes and their relevance across the diverse
HLA immune response genes of human populations. We
characterized CD4 T cell immunity to anthrax Lethal Factor
(LF), using HLA transgenic mice, as well as testing
candidate peptide epitopes for binding to a wide range
of HLA alleles. We identified anthrax epitopes, noteworthy
in that they elicit exceptionally strong immunity with
promiscuous binding across multiple HLA alleles and
isotypes. T cell responses in humans exposed to LF
through either natural anthrax infection or vaccination
were also examined. Epitopes identified as candidates
were used to protect HLA transgenic mice from anthrax
challenge.
Immunodominant Anthrax T Cell Immunity
PLOS Pathogens | www.plospathogens.org 2 May 2014 | Volume 10 | Issue 5 | e1004085
Figure 1. HLA transgenic mice immunized with LF generate an antigen-specific memory response to the LF protein and domains
which follows an HLA hierarchy and predominantly focuses upon domains II and IV. Mice (3–5 per HLA transgenic group) were
immunised in the footpad with 25 mg LF adjuvanted with Titermax Gold. Popliteal lymph nodes were harvested on day 10 and stimulated with either
(A) 25 mg of whole LF or (B) the individual LF domains. The results, expressed as SI (6 standard deviation) for, HLA-DR1 (n = 4), HLA-DQ8 (n = 4), HLA-
DQ6 (n = 5), HLA-DR15 (n = 4) and HLA-DR4 (n = 4), demonstrated a significant difference between strains. A significantly elevated response to LF was
Immunodominant Anthrax T Cell Immunity
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II and IV (Figure 1B), while the HLA-DQ8 transgenics response
to domain IV was significantly elevated relative to the domain I
response (Figure 1C). HLA-DR15 transgenic mice showed a
significantly elevated response to domain II alone (Figure 1E),
while HLA-DQ6 transgenic mice demonstrated significant
responses to domains II and IV (Figure 1D). HLA-DR4
transgenics respond to all four domains (Figure 1F). All of the
HLA transgenics used in this study generated a memory recall
to domain II of LF (Figure 1B–F). These results confirm that
HLA polymorphisms play a role in the differential response to
the domains of LF, and contrast with the corresponding lack of
response to LF domains in sham immunized HLA transgenic
mice (Supplementary Figure S1A).
LF contains several HLA class II binding regions including
a region of exceptionally high binding affinity across
distinct HLA polymorphisms
A peptide library of overlapping 20-mers representing the
complete anthrax LF sequence was evaluated for binding to seven
common HLA-DR alleles, DRB1*0101 (DR1), DRB1*0401
(DR4), DRB1*1101 (DR11), DRB1*0701 (DR7), DRB1*1501
(DR15), DRB1*0301 (DR3) and DRB1*1301 (DR13) (Table 1).
The region of the LF sequence encompassing amino acids 457–
486 contains at least 2 epitopes able to bind most or all HLA-DR
alleles tested with exceptionally high affinity. A further twelve
peptides, LF101–120, LF171–190, LF241–260, LF251–270, LF261–280,
LF457–476, LF574–593, LF594–613, LF604–623, LF644–663, LF674–693
and LF694–713, showed strong to moderate binding across all seven
HLA-DR alleles.
Characterization of LF CD4+ T cell epitopes demonstrates
the influence of HLA-DR and HLA-DQ polymorphisms
and reveals promiscuous, highly immunodominant
epitopes common to distinct HLA alleles
The immunodominant CD4+ T cell epitopes within LF were
mapped by immunizing HLA transgenics with recombinant LF
protein and restimulating draining lymph node cells with a
peptide library spanning the LF sequence. The resulting
epitope maps reveal a picture of HLA-restricted epitopes in
LF indicating that the immunodominant epitopes were largely
localized to domains II and IV (Figure 2). The immunological
memory to the LF peptides contrasted with the lack of
responses to the peptides in sham immunised HLA-DR4 mice
(Supplementary Figure S1B). The two epitopes shown to be
exceptionally high affinity binders to diverse HLA-DR alleles,
LF457–476 and LF467–486, located in domain II, not only elicited
very sizeable responses, but were both recognised by all LF
immunized HLA transgenics, suggesting that these epitopes
were both immunodominant and promiscuous in their HLA
binding. Whilst promiscuous peptides have been previously
identified which bind strongly to a number of distinct HLA-
DR or HLA-DQ molecules [36–38], the substantial differences
between the binding grooves of HLA-DR and HLA-DQ
isotypes [39–41] have resulted in the identification of a
relatively low number of peptides that can be presented by
such diverse isotypes [42]. These two LF epitopes, able to
stimulate CD4+ T cells at very high frequency and across HLA
class II differences are thus highly unusual and of considerable
interest both for efforts to understand immunity to anthrax and
to design universally stimulatory vaccines.
A number of regions that had shown strong HLA binding
affinity were indeed identified as functional, immunodominant
epitopes, with domain IV especially rich in epitopes able to
induce a strong in vivo response. CD4+ T cell responses to the
domain IV peptide, LF547–567, were identified in HLA-DR1,
HLA-DR4 and HLA-DR15 transgenic lines, indicating that this
epitope was presented solely by HLA-DR alleles. Two more
domain IV epitopes, LF724–743 and LF744–763, were both HLA-
DR4 and HLA-DR15 restricted. While domains II and IV
contained a number of HLA-DR restricted epitopes, the majority
of HLA-DQ8 restricted epitopes were found in domains I and II,
and the HLA-DQ6 restricted epitopes were located only in
domain II.
The greatest number of epitopes identified were DRB1*0101
restricted, with the HLA-DR1 transgenic strain recognising 14
epitopes, this was followed by 13 DQB1*0302 restricted epitopes.
Ten epitopes were DRB1*1501 restricted, and 7 DRB1*0401
restricted epitopes were identified, while only 2 DQB1*0602
restricted epitopes were identified.
Some HLA-restricted peptide epitopes were identified which
lay within regions of the LF protein not previously shown to elicit
a response when provided as a whole protein antigen. LF
immunized HLA-DR1 and HLA-DQ8 transgenics responded to
peptides located within domain I, which as an intact domain did
not elicit memory recall in the respective LF immunized
transgenic mice (Figure 1B and 1C); similarly LF immunized
HLA-DR4 and HLA-DR15 transgenics generated responses to
peptide epitopes in domain IV, which also did not demonstrate a
recall response following stimulation with the whole domain
(Figure 1E and 1F).
The HLA specific epitopes identified in mice transgenic for
DR1, DR4 and DQB1*0302 are modeled on the LF crystal
structure in Figure 3. Despite the heterogeneity which can be
observed in the range of LF peptides presented by the HLA
transgenics, there were identifiable areas rich in allele specific
immunodominant peptides, presumably indicative of structural
accessibility to cleavage by antigen processing enzymes. The T cell
responses to epitopes located in the catalytically active domain IV
were overwhelmingly dominated by HLA-DR presentation, as
only a single DQB1*0302 restricted epitope (LF594–613), and no
DQB1*0602 restricted epitopes, were identified in this substrate
recognition and binding domain. It is also possible to identify,
within the VIP2-like domain II, the cluster of epitopes containing
seen in HLA-DR1 compared to DQ6, DR15 and DR4 (p = 0.0013, One-way ANOVA, with Bonferroni’s multiple comparison). Cell cultures from mice
transgenic for (B) DR1, (C) DQ8, (D) DQ6, (E) DR15 and (F) DR4 were stimulated for 3–5 days with LF domains; proliferation was measured by 3H-
thymidine incorporation after 5 days stimulation (B, C & D), IFNc production was assayed by ELISpot development and enumeration after 3 days
stimulation (E & F). In HLA-DR1 transgenics (B) responses to domain I were significantly lower than responses to domains II and IV (p = 0.0081, Kruskal-
wallis, with Dunn’s multiple comparisons), while HLA-DQ8 transgenics (C) only showed a significant difference in response between domains I and IV
(p = 0.0174, Friedman with Dunn’s multiple comparisons). The response to the individual domains in HLA-DQ6 (D) showed significant variance
(p = 0.0002, One-way ANOVA with Tukey’s multiple comparisons) with the responses to domains II and IV significantly greater than the responses to
domains I or III. The response to the individual domains in HLA-DR15 (E) also differed significantly (p,0.0001, One-way ANOVA with Tukey’s multiple
comparisons), however, only the response to domain II was elevated compared to domains I, III and IV). Data is represented as the stimulation index
(SI) calculated as the mean cpm or IFNc production of triplicate wells in the presence of peptide divided by the mean cpm or IFNc production in the
absence of antigen. Results are given as the mean 6 SD/SEM.
doi:10.1371/journal.ppat.1004085.g001
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the immunodominant peptides LF457–476 and LF467–487, which
were presented by all the HLA transgenics.
Domain III, which has marked structural similarity to domain
II, possibly due to its origins as a duplication of this domain,
displays none of the immunogenicity associated with domain II
[43,44]. We observed no immunodominant T cell epitopes within
this domain in any of the HLA transgenic strains utilised in the
epitope mapping (Figures 1 and 2).
Figure 2. Epitope-rich, immunodominant regions of LF and epitopes common to diverse HLA polymorphisms. Popliteal lymph nodes
from mice transgenic for DRB1*0101 (A), DRB1*0401 (B), DRB1*1501 (C), DQB1*0302 (D) and DQB1*0602 (E) (n = 5) were harvested 10 days after
immunization with 25 mg LF adjuvanted with Titermax Gold and stimulated with 25 mg of each 10mer peptide in the LF peptide library (LF31–809).
Responses were considered positive if the response was$2 SD above the cells plus medium control. Data is represented as scatter plots, showing the
responses of individual mice as the stimulation index (SI) calculated as the mean cpm or IFNc production of triplicate wells in the presence of peptide
divided by the mean cpm or IFNc production in the absence of antigen. Results are given as the mean 6 SD/SEM.
doi:10.1371/journal.ppat.1004085.g002
Figure 3. Regions HLA-DR and DQ-presented anthrax LF epitopes mapped onto the LF protein structure reveals clustering of
immunogenic epitopes. The structural domains of LF protein are indicated in Roman numerals (A). Immunodominant epitopes identified in this
study from mice transgenic for DRB1*0101 (B), DRB1*0401 (C), and DQB1*0302 (D) are superimposed on the LF crystal structure (Protein Data Bank
accession code 1J7N). Roman numerals indicate the structural domains. Ribbon diagrams were generated using the Accelrys discovery studio client
2.5 program.
doi:10.1371/journal.ppat.1004085.g003
Immunodominant Anthrax T Cell Immunity
PLOS Pathogens | www.plospathogens.org 7 May 2014 | Volume 10 | Issue 5 | e1004085
T cell responses to LF in naturally infected anthrax
patients or AVP-vaccinees
While we had previously investigated responses of human
donors to epitopes within domain IV [32], it was important to
obtain a comprehensive picture of the immune responses of
human donors following either natural infection or vaccination.
Having shown in the more reductionist context of HLA
transgenics expressing single HLA class II heterodimers that LF
is highly immunogenic and epitope rich, one would expect an even
more complex picture in, heterozygote humans carrying multiple
HLA class II isotypes. We found a heterogeneous response, spread
across domains I–III of the entire protein, which was distinct
according to the nature of exposure to anthrax: epitopes that were
predominantly a feature of the response of vaccinees were rarely
recognized by the majority of infected donors or healthy controls,
and vice versa (Table 2).
In the AVP vaccinated individuals the immunodominant
response encompassed five epitopes. Of these peptides, LF41–60,
LF417–436, and LF437–456 did not induce a response in any of the
HLA transgenics (LF337–356 was identified as a cryptic epitope
which was identified in the HLA-DQ8 transgenics, data not
shown). The T cell responses to the domain I peptide LF101–120
was confirmed as an HLA-DQ8 specific response in the transgenic
mice.
In the naturally infected donors from Kayseri, however, the T
cell response was focused on two LF peptides. In parallel with the
epitope hierarchy identified in the AVP vaccinees, a peptide
epitope, LF281–300, was also identified which did not induce a
response in any of the HLA transgenics. The remaining domain II
peptide, LF467–487, had previously been identified as an immuno-
dominant HLA-promiscuous epitope, capable of eliciting a T cell
response from all the HLA transgenics.
We have previously documented immune responses to domain
IV in humans [32], however it is interesting to note that, of the
epitopes identified in that previous study, in AVP vaccinees,
LF674–693 has been confirmed as an immunodominant epitope in
both HLA-DR1 and HLA-DR15 transgenics, and the peptides
LF574–593, LF654–673 and LF694–713 were all identified as
immunodominant epitopes in this study, which each elicited a T
cell response in a single HLA transgenic strain. Furthermore, the
domain IV epitopes previously reported in Turkish naturally
infected anthrax patients, LF694–713 and LF714–733 have both been
identified as immunodominant epitopes in HLA-DR15 trans-
genics. Although the domain IV peptide LF584–603 which was a
feature of the AVP vaccinee’s immune response, did not induce
any response in any of the HLA transgenics in this study.
There was very little overlap in responses of the infected and
vaccinated human cohorts: the immunodominant, strongly bind-
ing epitope, LF467–486, was recognized by a high proportion of
naturally infected donors, but not vaccinated individuals. This
suggests that the peptide is processed and strongly immunogenic
during infection, but is not recognized in the response to the
protein antigen during immunization. Could epitope differences
between the cohorts be explained by the fact that the individuals
come from different geographical regions and express different
HLA class alleles? We report the HLA-typing of the donors, and
indeed the common HLA class II alleles present in the studied
region of Turkey are not substantially different from the common
alleles in the studied cohort regions of the UK. Ultimately, the
number of individuals in this study, powered for functional rather
than genetic association studies in its inception and design, is too
low to draw conclusions about the possibility that different HLA
allele frequencies may drive different preferences for immunodo-
minant epitopes.
The majority of HLA class II restricted epitopes characterised
by this study were identified by more than one experimental
system (Figure 4A). The most notable epitope, LF467–486 showed
strong or moderate HLA-DR binding affinity across a range of
alleles, and was immunogenic in HLA-transgenics and infected
humans.
A comparison of HLA-DR restricted peptides, showed the
overlapping subsets of allele specific and promiscuous epitopes
Table 2. Frequent, large CD4 T cell epitope responses to anthrax LF domain I–III peptide panel in immune human donors.
Human
cohorts HLA class II T cell response to anthrax LF domain I–III epitopes, SFC/10
6 cells
DR1 DRB3/4/5 DQB1
LF 41–
61
LF 101–
120
LF 281–
300
LF 337–
356
LF 417–
436
LF 437–
456
LF 467–
486
Infected
donor 2
4 4 53 53 8 8 0 0 345 0 0 0 323
Infected
donor 3
4 14 52 53 5 8 0 0 218 0 0 0 0
Infected
donor 6
11 13 52 52 6 11 0 0 0 0 0 0 291
Infected
donor 7
4 14 52 53 5 4 0 0 227 0 0 0 633
Vaccinee 3 11 13 52 52 6 7 1275 1357 0 1314 1322 1009 0
Vaccinee 4 15 7 51 53 2 6 473 509 0 0 837 451 0
Vaccinee 5 103 17 52 52 2 5 495 0 0 703 0 0 0
Vaccinee 6 1 13 52 52 5 6 0 0 0 0 0 416 0
Vaccinee 8 1 1 - - 5 5 0 0 0 0 725 0 0
Vaccinee 10 7 15 51 53 2 6 0 423 0 521 0 0 0
Frequent, large CD4 T cell epitope responses to anthrax LF domain I-III peptide panel in immune human donors. Table indicates positive T cell IFNc ELIspot responses
that were seen in 3 or more donors from the human donor cohort described in the Methods, comprising a total of 9 donors in the cutaneous anthrax (Kayseri) group
and 10 donors in the AVP vaccinees (UK) group.
doi:10.1371/journal.ppat.1004085.t002
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identified by binding affinity (Figure 4C) and immunogenicity in
HLA transgenic mice (Figure 4B). Although the binding affinity
assays suggest 21 peptides demonstrated strong or moderate
promiscuous binding to HLA-DR1, DR4 and DR15 (Figure 4C),
only three peptides, LF457–476, LF467–486 and LF547–568 were
immunogenic in all three HLA-DR transgenic strains analysed
(Figure 4B). It is interesting to note that, according to the binding
affinity studies LF467–486 and LF547–568, but not LF457–476, were
strong binders to all three HLA-DR alleles (Table 3), demonstrat-
ing the importance of validating the immunogenicity of T cell
epitopes in vivo.
It is important to recognise the limitations of this study; the
strength of HLA binding is based exclusively on seven HLA-DR
alleles, whilst all of the human cohorts presented the peptides
through a diverse and heterogeneous mixture of HLA class II
alleles. Nonetheless, it is striking that LF467–486 not only showed
strong binding affinity across all HLA-DR alleles assayed, but all 5
HLA transgenic strains and in infected individuals, showed strong
T cell responses to this peptide (Tables 1 and 2), demonstrating a
truly promiscuous HLA class II binding and immunogenic nature.
Immunization of HLA transgenics with an LF fusion
protein or a peptide cocktail of LF T cell epitopes confers
protection from anthrax challenge
The primary importance of humoral immunity in mediating
protection against anthrax has been brought into question by
recent studies suggesting that IFNc producing CD4+ T cells play
an important role in long lasting immunity [32,45]. In addition,
induction of memory CD4+ T cells may feedback not only to
cellular immunity, but also aid in the production of toxin
neutralising antibodies, Ig class switching and B cell affinity
maturation. To determine whether the immunodominant T cell
epitopes identified within LF could be incorporated into an
epitope string vaccine capable of conferring protection against
lethal anthrax challenge in a mouse model, the HLA-DQ8
transgenic mice were immunized with either a fusion protein
comprising HLA-DQ8 restricted epitope moieties expressed
contiguously after a tetanus toxin helper domain, or a cocktail of
the same epitopes as synthetic peptides.
HLA-DQ8 transgenics primed and boosted with 3 doses of an
LF fusion construct containing HLA-restricted LF epitopes were
fully protected against challenge with 106 cfu B.anthracis STI. The
naı¨ve, sham immunized group showed a significantly lower
survival rate than either the group primed and boosted with 3
doses of the pooled peptides which were expressed in the fusion
protein (p.0.01) or the fusion protein (p.0.01) immunized groups
(Figure 5A). Only 2/6 naı¨ve mice survived to day 20 post-
infection, with a median survival time of 6 days in this group. The
bacterial loads recovered from the spleens of surviving mice
showed that the immunized mice appeared to clear the infection
more successfully than the naı¨ve mice, (naı¨ve group (1883.4+/
2317 cfu), peptide cocktail (801.2+/2469 cfu) and LF fusion (153
+/254 cfu)), however it was not possible to detect a significant
difference between groups in terms of bacterial burden (Figure 5B).
The high degree of protection against anthrax infection observed
in both the immunized groups indicated, not only that the LF
fusion protein was capable of conferring the same protective affect
as the individual peptides, but also validated the immunoprotec-
tive effects of the epitopes identified within this study. Evaluation
of peptide-specific responses on a second group of HLA-DQ8
transgenic mice immunized with either LF fusion protein or
peptide cocktail showed that the strongest peptide recall in both
groups was to LF467–486 (data not shown). These data suggest that
LF467–486 and the promiscous epitopes which were included in
these immunisations prime a strong T cell response, playing a role
in protection against anthrax.
Discussion
While considerable attention has been devoted to the profound
immune subversion mediated by anthrax toxins [46], recent
human studies, including this one, show that anthrax infection can
be immunogenic [4]. The role of LT in the disruption of the
MAPK signalling pathways, with its consequences for the
apoptosis of antigen presenting cells, specifically the lysis of
dendritic cells and macrophages, might be expected to subvert
host immunity and promote systemic anthrax infection. However,
investigation of the inverse relationship between sensitivity to LT
and resistance to infection, indicates that mice which possess alleles
encoding an LT-sensitive form of Nlrp1b promote a pro-
inflammatory response predominantly driven by inflamasome-
mediated cell lysis and release of IL-1b [47–50]. The associated
cell infiltration and cytokine milieu seen in early inflammation
may be crucial in driving antigen presentation and T cell priming.
Recent studies ranging from asymptomatic seroconversion of
wool-workers to our own recent work with near lethal anthrax
infection in intravenous drug users, show common themes in terms
of strong induction of adaptive immunity [4,25].
For an infection in which we believe there is a key role of host
Th1 immunity, it would be assumed that IgG2a neutralizing
antibodies would be an important correlate of protection.
However, since the most relevant studies in which this can be
analyzed in detail tend to be primate studies based on protection
by alum-adjuvanted vaccine, it is the vaccine formulation itself
that tends to be the main driver of protective IgG subclasses, both
IgG1 and IgG2a being found in the protective response [51].
LF protein boosts PA-specific antibody responses following co-
administration [30,52], and the incorporation of a truncate
containing the N-terminal region of LF into a PA plasmid
expression vector enhances the PA-specific antibody response [52],
while LF truncated proteins are capable of conferring protection
against B. anthracis aerosol challenge [53,54]. Thus LF-specific
responses may be more important mediators of protective
immunity than previously thought. Previous work by our lab has
identified LF as a major target of T cell immunity in humans [32],
despite the amount of LF released by B. anthracis being one-sixth
that of PA [55].
Antigen presentation through both HLA-DR and DQ is
important in the induction of immunity, and the allelic diversity
inherent in these class II molecules shapes the T cell repertoire and
influences susceptibility to infection [56]. The reductionist
approach of using transgenic models was deployed here as a
means of defining HLA restricted T cell responses to immunogenic
epitopes of LF. Across the transgenic lines, representing five HLA
class II alleles, along with the expected allele specific epitopes, the
Figure 4. Overview of allele specific and promiscuous epitopes identified by binding affinity, and immunogenicity in HLA
transgenic mice and human subjects. The overlapping relationships of the epitopes identified in the HLA transgenic responses, HLA-DR binding
affinity studies, and in cohorts of vaccinated and infected humans, were demonstrated in a Euler diagram (A). The HLA-DR restricted epitopes
identified in (B) HLA transgenic mice and (C) HLA binding affinity studies were visualised as Venn diagrams, to show allele specific and promiscuous
epitopes.
doi:10.1371/journal.ppat.1004085.g004
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T cell response showed a number of broad similarities. This was
most evident in the response to LF domain II, which produced
immunogenic responses in both HLA-DR and DQ transgenic
mice following stimulation with either the whole domain, or the
individual peptides LF457–476 and LF467–487, which dominate the
T cell response to this domain. These immunodominant epitopes,
which were also found to have a high binding affinity for a wide
range of HLA-DR molecules, therefore comprise ‘public specific-
ities’ or promiscuous epitopes which are efficiently presented by
APCs, to a peptide-MHC specific TCR repertoire, in all HLA
transgenics (Table 3).
The C-terminal domain II of LF shows structural homology
with the ADP-ribosyltransferase found in the Bacillus cereus VIP2
toxin. In conjunction with domains III and IV, domain II forms
the active site which is involved in substrate recognition and
binding [57]. The amino terminus of the MAPK kinases substrates
fit into the LF groove which contains several, conserved, long
chain, aliphatic residues [58]. These residues occur in three
distinct clusters; the first is composed of Ile298, Ile300, Ile485,
Leu494, and Leu514, the second cluster of residues contains Ile322,
Ile343, Leu349, Leu357, and Val362 which lie at the end of the
catalytic groove. The final cluster of aliphatic residues lies close to
the domain IV groove; Leu450, Ile467, Leu677, Leu725, and Leu743
[58]. Both of the immunodominant epitopes LF457–467 and LF467–
487 overlap two of the aliphatic residues, Ile467 and Ile485 which
may have an effect upon the substrate binding of MAPK kinases.
It is tantalising to note that the host response focuses on this active
site, for which the evolutionary cost of mutation would be high for
the pathogen; one must of course note, however, that anthrax is
not an obligate human pathogen, is not commonly spread between
people and can survive in spore form in soil. Thus, this is not an
infection where there is likely to be an overt host-pathogen arms
race.
The T cell responses to the peptide LF547–567, from domain IV,
appeared to be HLA-DR restricted, as only T cells from the DR
transgenics, HLA-DR15, HLA-DR4 and HLA-DR1, not the DQ
transgenics HLA-DQ6 and HLA-DQ8, responded to this peptide.
Domain IV is the catalytically active center of the LF toxin [43],
and its protein folds contain a sequence which shares similarity
with the zinc-dependant metalloproteases found in the toxin
produced by C. tetani [59]. Previous work has indicated that this
homologous region of the tetanus toxin contains a number of
HLA-DR restricted T cell epitopes [60]. The ability of the LF
domain IV to readily provoke a recall response in CD4+ T cells in
the HLA-DR transgenics, suggests that the immune response to
this particular domain of the LF protein is also dominated by
HLA-DR restricted T cells. It has been observed that mutations in
the sequence coding for domain IV disrupts the substrate binding
groove created by domains II, III and IV, eliminating the
peptidase activity of LF, and thereby abrogating its toxicity [61].
The putative zinc binding site [HEFGHAV] which occurs
between the amino acid residues LF686 and LF690 [62] was only
a feature of the HLA-DR1 transgenic response to LF674–693
A number of immunodominant epitopes identified within LF
showed broad HLA binding characteristics, most notably the
domain II epitopes LF457–476 and LF467–487 which showed strong
binding across a range of HLA-DR molecules as well as the
preponderance of epitopes from domain IV which were presented
by HLA-DR. The strength of HLA binding does not however
appear to predict the immunodominance of the peptide epitope.
This contrasted with a number of studies, which have described a
strong correlation between the affinity of binding and the ability of
a peptide to be presented by a particular MHC molecule resulting
in an immunodominant T cell response [63–66].
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Of the five HLA strains challenged with domain I peptides, only
the HLA-DR1 and HLA-DQ8 transgenics showed CD4+ T cell
responses to peptide epitopes from this domain. Domain I binds
with high affinity to the proteolytically active 63 kD PA heptamers
which are responsible for the membrane-translocation of the
anthrax toxins [67]. Over the first 250 residues, this domain shares
significant sequence identity and similarity with domain I of EF
[43]. The N-terminal sequence of both toxins contain a common
domain for PA binding, which in LF has been shown to be
sufficient to act alone as a carrier for delivery of heterologous
proteins across membranes in the presence of PA [68]. The
sequence homology between the two toxins within domain I was
demonstrated by the use of LF induced antibodies which were
cross-reactive with EF [69]. One of the cross-reactive epitopes
LF265–274 (which corresponds to EF257–268), overlapped with the
HLA-DR1 restricted T cell epitopes LF251–270 and LF261–280,
indicating that these epitopes have the potential to induce a
neutralising antibody response to both LF and EF as well as the T
cell response, making them interesting candidates for inclusion in a
polyepitopic anthrax vaccine. In contrast to domain IV peptides,
epitopes in this domain are presented in the context of both DR
and DQ, although there appears to be minimal overlap in the
specific peptides presented.
None of the transgenics showed immunodominant CD4+ T
lymphocyte responses against the individual peptides which make
up domain III. The helix bundle which makes up domain III is
inserted into domain II, and may have arisen from repeated
duplications of a structural element of domain II [40]. Although
these domains share elements of their structure and function, the
CD4+ T cell response to each is very different. Domain III appears
to be a hidden or infrequent target of the immune response.
Most vaccine strategies against anthrax have concentrated on
PA, although the UK AVP vaccine, which contains both PA, and
lower levels of LF, stimulates LF specific antibodies [70–72], while
exposure to natural infection results in a faster, antibody response
to LF than PA [73]. It was discovered that the magnitude of the
CD4+ T cell response to LF antigens was greater in naturally
infected individuals than in vaccinees [32]. The T cell immunity to
LF, particularly domain IV, identified in naturally infected
individuals is in contrast to the expected response to LF exposure,
especially in the context of infection, which might be expected to
impair the T cell memory of B. anthracis in survivors of natural
infection. Taking into account all the HLA-DP, DQ and DR
products, as well as inter and intra isotypic mixed pairs, a
heterozygous human can present peptides for CD4+ T cell
recognition on up to 12 different class II molecules. It is therefore
interesting to note that despite the immunogenetic heterogeneity
seen in human populations, which along with differences in
exposure to the antigen, might be expected to complicate the
pattern of epitopes recognised by the human cohorts studied,
amongst the naturally infected individuals, the immunodominant
promiscuous LF467–487 epitope was one of the main targets of a
strong CD4+ T cell response.
Some CD4 epitopes identified in human vaccinees were not
seen in the naturally infected individuals; it might be expected that
some epitopes present in the context of vaccination would be lost
on infection. It is unclear whether such changes in antigen focus
reflect differential antigen processing of pathogen proteins
Figure 5. An LF epitope based vaccine which stimulates HLA restricted T cell immune responses may confer protection against B.
anthracis challenge. Groups of HLA-DQ8 transgenic mice were immunised 3 times, on days 0, 14 and 35 by the intra-peritoneal route, with either an
LF fusion construct comprising a tetanus toxin helper domain (aa 865–1120) and 12 confirmed HLA-restricted LF epitopes (n = 6, black diamonds), or
a peptide pool of the LF epitopes expressed in the fusion protein (n = 7, black triangles), a control, sham immunised, group was also included in the
experiment (n = 6, black squares). All groups were challenged with 106 cfu B. anthracis STI by the intra-peritoneal route, on day 77, and monitored
daily for survival (A). The impact of infection upon survival was described using Kaplan Meier estimation (A). Spleens were recovered from surviving
mice at day 21, (LF fusion protein (n = 6, black diamonds), peptide pool (n = 7, black triangles) and sham immunized mice (n = 2, black squares)), and a
mean bacterial count per spleen determined following culture of B. anthracis for 24 hours (B). No statistically significant difference was seen between
the groups in terms of bacterial burden.
doi:10.1371/journal.ppat.1004085.g005
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encountered in vaccination in contrast to infection, or if this
represents an artefact of the repeated AVP vaccinations which
may skew the cytokine environment during induction of the
immune response, impacting upon the T cell epitope repertoire
[74]. Humans exposed to LF following cutaneous anthrax
infection generate robust long-term T cell memory to B. anthracis
epitopes, in many cases several years after the initial infection
event. The T cell response in these naturally infected individuals
showed significantly elevated levels of the pro-inflammatory
cytokines associated with Th1, Th2, Th9 and Th17 subsets
compared to vaccinees and naı¨ve controls [32]. The inhibitory
effects of both LT and ET upon expression of the activation
markers CD25 and CD69 and the secretion of the pro-
inflammatory cytokines IL-2, IL-5, TNFa, and IFNc by human
T cells has been described in vitro [75,76]. Murine lymphocytes
show impaired TCR-mediated activation and T cell dependent
production of IL-3, IL-4, IL-5, IL-6, IL-10, IL-17, TNFa, IFNc
and GM-CSF following exposure to LT and ET [77]. However,
the cellular immunity we have identified within the naturally
infected humans indicates that, although in vitro exposure to ET
has been implicated in immune deviation towards both the Th2
and Th17 pathways [78,79], the human immune response against
LF encompasses a strong IFNy response. It was suggested to the
authors that, since the predominant mechanism of protective
immunity to anthrax toxin is antibody neutralization, it is possible
that T follicular helper cells, characterised by the co-production of
IFNc and IL-21 and vital for B cell help, may be important here.
In response to the reviewer’s suggestion, we have considered the
notion that this is a TFH response by looking for IL-21
accompanying the IFNc response in each of our donor responses,
but, as we now report, detected none; we therefore consider it less
likely that these are predominantly TFH cells.
Despite the presence of many potential peptide epitopes within
LF, the elicited T cell response indicates that immunodominant
LF epitopes are concentrated in domains II and IV. The
immunodominant epitopes identified within these domains appear
to comprise essential residues of LF which are critical for efficient
catalytic activities and the execution of substrate cleavage. We
therefore suggest that a number of the immunodominant epitopes
which we have identified represent regions of the LF protein in
which the cost of mutation to B. anthracis would be too high, due to
the resultant loss of function. The identification of the immuno-
dominant epitope LF467–487, which represents a rare truly
promiscuous antigen, capable of binding strongly to multiple
diverse HLA alleles, and which is also a feature of a robust T cell
response in naturally infected individuals, presented us with a
unique opportunity to develop a polyepitopic vaccine in which
each epitope is promiscuous, or covers a number of HLA alleles.
This increases the chance that each individual in a genetically
heterogeneous population acquires immunity to multiple epitopes
from a pathogen, thus offering increased protection to a
population. We found that the 12 HLA-restricted LF epitopes,
either incorporated as a fusion construct or as a peptide pool,
conferred protection against lethal challenge with B. anthracis. In
addition to their defined role in the T cell response to LF antigens
in vitro, this suggests that the epitopes we have described here are
capable of priming a strong, long-lasting T cell response that play
a role in protection against anthrax. Further work to attribute this
protection to a specific response, through both cellular and
humoral markers, would be of merit in determining the potential
of the LF fusion protein as a future anthrax vaccine candidate.
The nature of anthrax infection and the need to evolve tractable
strategies, notably in a biodefense setting, has necessarily led to a
reliance on a program of PA vaccines tested in primate challenge
studies. Study of immunity in naturally-exposed humans, who
seem to be immune to reinfection, raises the possibility of learning
from these immune repertoires, including the role of LF as a
target.
Materials and Methods
Expression and purification of LF antigens
Recombinant full-length LF (rLF) and individual domains were
produced in an E. coli expression system as previously described
[80]. In brief, the cysteine residue at position 687 was replaced
with glutamic acid to produce a biologically inactive form of LF.
The gene sequence of LF was codon optimized for expression in E.
coli (GenScript, USA) to allow for the high AT nucleotide content
of the protein. Using the pQE30 expression system (Qiagen,
Germany) the full length LF and LF domain sequences were
cloned and expressed from E. coli as recombinant N-terminal
histidine-tagged proteins. Bacterial pellets were disrupted using a
French press, and the target proteins recovered by centrifuging for
20 minutes at 450006g at 4uC. These were then incubated with
Talon metal affinity resin (Clontech, USA) to bind the N-terminal
histidine tag. The proteins were eluted from this resin at 4uC by
washing with protein elution buffer. Protein concentration was
determined using a bicinchoninic acid (BCA) protein assay
protocol (Pierce, Thermo Scientific, USA) and dialyzed against
HEPES buffer, using a 10000 molecular weight cut-off dialysis
cassette (Pierce, Thermo Fisher Scientific, USA), to a final
endotoxin level of ,4 EU/mg. A synthetic peptide panel, HPLC
purified to a purity of $98% purity, comprising of 20mer amino
acids overlapping by 10 amino acids encompassing the full-length
sequence of LF were obtained from a commercial supplier
(Abgent, USA). All peptides were resuspended in DMSO at
25 mg/ml.
HLA transgenic mice
HLA class II transgenic mice carrying genomic constructs for
HLA-DRA1*0101/HLA-DRB1*0101 (HLA-DR1), HLA-DRA1*
0101/HLA-DRB1*0401 (HLA-DR4), HLA-DRA1*0101/HLA-
DRB1*1501 (HLA-DR15), HLA-DQA1*0301-DQB1*0302
(HLA-DQ8) and HLA-DQA1*0102/HLA-DQB1*0602 (HLA-
DQ6), crossed for more than six generations to C57BL/6 H2-
Ab00 mice, were generated and described previously [81–86]. All
experiments were performed in accordance with the Animals
(Scientific Procedures) Act 1986 and were approved by local
ethical review.
Ethics statement
All mouse experiments were performed under the control of
UK Home Office legislation in accordance with the terms of the
Project License granted for this work under the Animals (Scientific
Procedures) Act 1986 having also received formal approval of the
document through the Imperial College Ethical Review Process
(ERP) Committee. Human blood samples for the Kayseri (Turkey)
component of this study were obtained with full review and
approval by The Ethics Committee of the Faculty of Medicine,
Erciyes University; all participants were adults over 18 year old.
Participants were given a full, verbal explanation of the project
and written consent was obtained from all those who elected to
participate. Human vaccinees based at DSTL, Porton Down,
participated in the context of a study protocol approved by the
CBD IEC (Chemical and Biological Defence Independent Ethics
Committee); the subjects were all adults aged over 18 years and all
provided written, informed consent. Healthy control blood
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samples were collected under the approval of Ethics REC
reference number 08/H0707/173.
Live B. anthracis challenge
HLA-DQ8 transgenic mice were challenged intra-peritoneally
with 106 colony forming units of B. anthracis STI strain. The
animals were monitored daily for 20 days post-infection, and post-
mortem spleens were homogenized in 1 ml of PBS prior to plating
out at a range of dilutions onto L-agar plates. Colonies were
counted after 24 hours culture at 37uC, and the mean bacterial
count per spleen was determined.
Patient samples
Leukocytes were isolated from human peripheral blood samples
and stimulated as described previously [32]. In brief, sodium
heparinised blood was collected with full informed consent from 9
Turkish patients treated for cutaneous anthrax infection within the
last 8 years. (Ericyes University Ethical Committee), 10 volunteers
routinely vaccinated every 12 months for a minimum of 5 years
with the UK Anthrax Vaccine Precipitated (AVP) vaccine (UK
Department of Health under approval by the Convention on
Biological Diversity Independent Ethics Committee for the UK
Ministry of Defence), and 10 age-matched healthy controls with
no known exposure to anthrax antigens (Ethics REC reference
number 08/H0707/173). PBMCs were prepared from the blood
using Accuspin tubes (Sigma, Dorset, UK) and washed twice in
AIM-V serum free medium (Life Technologies, UK). Cells were
counted for viability and resuspended at 26106 cells/ml.
LF epitope mapping and confirmation
Mice were immunized in the hind footpad with 50 ml of 12.5 mg
rLF, LF peptides, individual LF domains or a control of PBS,
emulsified in an equal volume of Titermax Gold adjuvant (Sigma-
Aldrich, USA). After 10 days, immunized local draining popliteal
lymph nodes were removed and disaggregated into single cell
suspensions. Lymph node cells (3.56106/ml) were challenged with
25 mg/ml of either recombinant full-length LF, the 4 domains
which comprise the LF protein, or the overlapping 20mer peptides
covering the full-length LF sequence. This generated a map of the
entire LF protein sequence. To confirm the immunodominant
epitopes identified by this large scale mapping, mice were then
immunized subcutaneously with 12.5 mg of the individual LF
peptides in Titremax adjuvant. After 10 days the lymph node cells
were challenged in vitro with 25 mg/ml of the recombinant full-
length LF and the immunising and two flanking LF peptides.
In the human T cell assays, the peptide library was prepared in
a matrix comprising 6 peptides per pool, so that each peptide
occurred in 2 pools but no peptides occurred in the same two
pools. This allowed the determination of responses to individual
peptides. The in-well concentration of each peptide was 25 mg/ml
and total peptide concentration per well was 150 mg/ml.
Lymphocyte proliferation assay
Leukocytes were resuspended at 3.56106 cells/ml in HL-1
media (1% L-Glutamine, 1% Penicillin Streptomycin, 2.5% b-
Mercaptoethanol) and 100 ml/well was plated out in triplicate on
96 well Costar tissue culture plates (Corning Incorporated, USA).
The cells were stimulated with 100 ml/well of, appropriate
antigen, positive controls of 5 mg/ml Con A (Sigma-Aldrich,
USA) or 25 ng/ml of SEB (Sigma-Aldrich, USA) or negative
controls of medium alone. The plates were incubated at 37uC, 5%
CO2 for 5 days. Eight hours prior to harvesting, 1 mCi/well of
[3H]-Thymidine (GE Healthcare, UK) was added. The cells were
harvested onto fiberglass filtermats (PerkinElmer, USA) using a
Harvester 96 plate harvester (Tomtec, USA) and counted on a
Wallac Betaplate scintillation counter (EG&G Instruments,
Netherlands). Results were expressed as stimulation index (SI)
(cpm of stimulated cells divided by cpm of negative control cells).
An SI of $2.5 was considered to indicate a positive proliferation
response.
IFNc ELISpot assay
Quantification of murine antigen-specific IFNc levels was
carried out by ELISpot (Diaclone) analysis of T cell populations
directly ex vivo. Hydrophobic polyvinyldene difluoride membrane-
bottomed 96-well plates (MAIP S 45; Millipore) were pre-wetted
with 70% ethanol, washed twice and then coated with anti-IFNc
monoclonal antibody at 4uC overnight. After blocking with 2%
skimmed milk, plates were washed and 100 ml/well of antigen was
added in triplicates. For each assay a medium only negative and a
positive control of SEB (25 ng/ml) were included. Wells were
seeded with 100 ml of 26106cells/ml in HL-1 medium (1% L-
Glutamine, 1% Penicillin Streptomycin, 2.5% b-Mercaptoethanol)
and plates were incubated for 72 h at 37uC with 5% CO2. Plates
were washed twice with PBS Tween 20 (0.1%) then incubated with
biotinylated anti-INFc monoclonal antibody. Plates were washed
twice with PBS Tween 20 (0.1%), and then incubated with
streptavidin-alkaline phosphatise conjugate, washed and then
treated with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue
tetrazolium (BCIP/NBT) and spot formation monitored visually.
The plate contents were then discarded and plates were washed
with water, then air-dried and incubated overnight at 4uC to
enhance spot clarity. Spots were counted using an automated
ELISpot reader (AID), and results were expressed as delta spot
forming cells per 106 cells (DSFC/106) (SFC/106 of stimulated
cells minus SFC/106 of negative control cells). The results were
considered positive if the DSFC/106 was more than two standard
deviations above the negative control.
Human T cell INFc levels were quantified by ELISpot
(Diaclone) as previously described [32]. In brief, the plates were
prepared in a similar manner to the murine ELISpots and
following addition of antigen to the wells (with each peptide
represented in two separate triplicates) they were frozen at 280uC
until use. Wells were seeded with 100 ml of human PBMCs at
26106 cells/ml (range; 1.66106–2.16106 cells/well) in AIM-V
medium and plates were incubated for 72 hours at 37uC with 5%
CO2. 50 ml supernatant was removed from each well for further
determination of cytokines, the remaining plate contents were then
discarded and plates were washed with PBS Tween 20 (0.1%) and
incubated with biotinylated anti–INFc, followed by a further wash
and the addition of streptavidin-alkaline-phosphatase conjugate.
Following a final wash, plates were developed by addition of
BCIP/NBT. Spots were counted using an automated ELISpot
reader (AID), and results were expressed as delta spot forming cells
per 106 cells (DSFC/106) (SFC/106 of stimulated cells minus SFC/
106 of negative control cells). The results were considered positive
if the DSFC/106 was more than two standard deviations above the
negative control and $50 spots. IL-21 release from peptide-
stimulated donor T cell cultures was determined by ELISA
(eBiosciences).
HLA peptide binding assay
Competitive ELISAs were used to determine the relative
binding affinity of LF peptides to HLA-DR molecules, as
previously described [87]. Briefly, the HLA-DR molecules were
immunopurified from homozygous EBV-transformed lymphoblas-
toid B cell lines by affinity chromatography. The HLA-DR
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molecules were diluted in HLA binding buffer and incubated for
24 to 72 hours with an appropriate biotinylated reporter peptide,
and a serial dilution of the competitor LF peptides. A control of
unlabeled reporter peptides was used as a reference peptide to
assess the validity of each experiment. 50 ml of HLA binding
neutralisation buffer was added to each well and the resulting
supernatants were incubated for 2 hours at room temperature in
ELISA plates (Nunc, Denmark) previously coated with 10 mg/ml
of the monoclonal antibody L243. Bound biotinylated peptide was
detected by addition of streptavidin-alkaline phosphatase conju-
gate (GE Healthcare, Saclay, France) and 4-methylumbelliferyl
phosphate substrate (Sigma-Aldrich, France). Emitted fluorescence
was measured at 450 nm post-excitation at 365 nM on a Gemini
Spectramax Fluorimeter (Molecular Devices, St. Gregoire,
France). LF peptide concentration that prevented binding of
50% of the labeled peptide (IC50) was evaluated, and data
expressed as relative binding affinity (ratio of IC50 of the LF
competitor peptide to the IC50 of the reference peptide which
binds strongly to the HLA-DR molecule). Sequences of the
reference peptide and their IC50 values were as follows: HA 306–
318 (PKYVKQNTLKLAT) for DRB1*0101 (4 nM), DRB1*0401
(8 nM), and DRB1*1101 (7 nM), YKL (AAYAAAKAAALAA)
for DRB1*0701 (3 nM), A3 152–166 (EAEQLRAYLDGTGVE)
for DRB1*1501 (48 nM), MT 2–16 (AKTIAYDEEARRGLE) for
DRB1*0301 (100 nM) and B1 21–36 (TERVRLVTRHIYNREE)
for DRB1*1301 (37 nM). Strong binding affinity was defined in
this study as a relative activity ,10, and a moderate binding
affinity was defined as a relative activity ,100.
Generation and evaluation of an LF epitope fusion
protein
A fusion protein comprising HLA-restricted T cell epitopes
from LF downstream of the universal T cell helper domain from
the tetanus toxin C fragment (aa 865–1120) was designed and
codon optimized to reflect Salmonella enterica Typhi codon usage
(GenScript Corp). This construct was expressed as a recombinant
N terminal histidine tagged protein on the commercially available
expression system pQE30 in E. coli M15 (Qiagen). The LF
epitopes included in the fusion protein were: LF101–120, LF151–170,
LF261–280, LF467–486, LF547–567, LF574–593, LF614–633, LF654–673,
LF674–693, LF714–733, LF724–743 and LF744–763. Briefly, cultures
derived from a single colony were grown overnight at 37uC in LB
broth with antibiotic selection. Overnight cultures were subcul-
tured in fresh LB broth until they reached an OD600 of 0.550–
0.600. To induce protein expression, isopropyl b-D-thiogalacto-
pyranoside (IPTG) was added to a final concentration of 1 mM.
Cultures were then incubated at 25uC (200 rpm) for 16 hours.
Cells were harvested by centrifugation at 10,000 g at 4uC for
20 minutes. His-tagged fusion proteins were purified from
bacterial pellets under denaturing conditions; all steps were
conducted at 4uC unless otherwise stated. The bacterial pellet
was resuspended in suspension buffer (SB) (50 mM NaH2PO4,
300 mM NaCl, pH 7) by gentle pipetting until a homogenous
suspension was obtained. Phenylmethanesulfonylfluoride (PMSF)
and lysozyme (Sigma- Aldrich, St. Louis, MO) were added to final
concentrations of 1 mM and 0.25 mg/mL respectively. The
suspension was stirred for 20 minutes before the addition of
deoxycholic acid (Sigma- Aldrich, St. Louis, MO) to a final
concentration of 1 mg/mL. The lysate was incubated at 37uC,
with occasional stirring, until viscous, and DNase I added to a
concentration of 0.01 mg/mL. The lysate was stored at room
temperature until no longer viscous before centrifugation at
10,000 g for 20 minutes. The resulting pellet was washed three
times in SB containing 1% Triton X-100, then washed in SB
containing 2M urea before resuspension in SB containing 8M urea
and centrifugation at 13,000 g for 15 minutes. The supernatant
was collected and incubated with Talon metal affinity resin
(Clontech Laboratories) to bind the N terminal histidine tag.
Following washing of the resin with SB containing 6 M urea, the
protein was recovered at 4uC in elution buffer (150 mM
imidazole, 50 mM sodium phosphate and 300 mM NaCl, 6 M
urea, pH 7). Eluate was dialyzed using a 10,000 MW cut off
dialysis cassette (Pierce, Thermo Scientific) in dialysis buffer (DB)
(10 mM HEPES, 50 mM NaCl, 400 mM L-Arginine, pH 7.5)
containing sequentially decreasing concentrations of urea for
1 hour periods. Finally, eluate was dialyzed against 4 L HEPES
buffer (10 mM HEPES, 50 mM NaCl, pH 7.5). Protein identity
was confirmed by SDS-PAGE and Western Blot analysis (Bio-Rad
Laboratories). Protein bands were detected by staining with
Coomassie Blue after electrophoretic transfer onto polyvinylidene
difluoride membranes (Millipore) by Ni-NTA HRP Conjugate
(QIAgen Inc.). The protein was of expected size and was
recognized by specific antibodies. The endotoxin content of the
different protein preparations was determined by the Limulus
amoebocyte lysate linetic-QCL assay according to the manufac-
turer’s instructions (Lonza). Protein concentrations were deter-
mined using a BCA protocol (Pierce, Thermo Scientific) [88].
The complete amino acid sequence of the fusion protein is:
MKNLDCWVDNEEDIDVILKKSTILNLDINNDIISDISGFNS-
SVITYPDAQLVPGINGKAIHLVNNESSEVIVHKAMDIEYN-
DMFNNFTVSFWLRVPKVSASHLEQYGTNEYSIISSMKK-
HSLSIGSGWSVSLKGNNLIWTLKDSAGEVRQITFRDLP-
DKFNAYLANKWVFITITNDRLSSANLYINGVLMGSAEI-
TGLGAIREDNNITLKLDRCNNNNQYVSIDKFRIFCKALN-
PKEIEKLYTSYLSITFLRDFWGSDVLEMetYKAIGGKIYIV-
DGDYVYAKEGYEPVLVIQSSEDYQHRDVLQLYAPEAFN-
YMetDKFKIYLYENMetNINNLTATLGADLENGKLILQR-
NIGLEIKDVQIEYIRIDAKVVPKSKIDTKIQKLITFNVHN-
RYASNIVESAYYLVDGNGRFVFTDITLPNIAEQYTHQDE-
IYEQVHSKGLYVAVDDYAGYLLDKNQSDLVTNSKKFID-
IFKEEGSNLTSYGRSEGFIHEFGHAVDDYAGYLL. Mice trans-
genic for HLA-DQ8 were immunized with 25 mg of fusion protein, or
alternatively with a peptide pool consisting of 25 mg of each peptide
represented in the fusion protein (total concentration 300 mg peptide),
control mice were sham-immunized with PBS. All immunizations were
adjuvanted 1:1 in Titremax Gold and administered by the i.p. route
(0.1 mL). Mice were immunized on days 0, 14 and 35 prior to
challenge with B. anthracis STI strain on day 77.
Supporting Information
Figure S1 HLA-DR4 transgenic mice sham immunized
with a PBS control do not generate a response to either
the LF protein, its domains, or the individual peptides
which make up the entire protein. HLA-DR4 transgenic
mice (n = 3) were immunised in the footpad with PBS adjuvanted
with Titermax Gold. Popliteal lymph nodes were harvested on day
10 and stimulated with 25 mg of either (A) the whole LF protein or
the individual domains or (B) the 10mer peptides in the LF peptide
library (LF31–809). IFNc production was assayed by ELISpot
development and enumeration after 3 days stimulation. Data is
represented as scatter plots, showing the responses of mice as the
stimulation index (SI) calculated as the mean IFNc production of
triplicate wells in the presence of peptide divided by the mean
IFNc production in the absence of antigen. Responses were
considered positive if the response was $2 SD above the cells plus
medium control.
(TIF)
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